Author

Carlo Derecho

Observed names: C. Derecho, CARLO DERECHO

Institution: Johnson & Johnson (United States)

Observed institutions: Johnson & Johnson (United States), University of Liège

OpenAlex ID: A5010802811

Development of a Multiplexed Urine Assay for Prostate Cancer Diagnosis

2008 · Tatiana Vener, Carlo Derecho, et al. · Clinical Chemistry · 59

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

2011 · Judith E. Karp, Tatiana I. Vener, et al. · Blood · 28

Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer

2013 · HAIYING WANG, JULIAN MOLINA, et al. · Molecular and Clinical Oncology · 15

Melanoma-Specific Marker Expression in Skin Biopsy Tissues as a Tool to Facilitate Melanoma Diagnosis

2010 · Doru T. Alexandrescu, C. Lisa Kauffman, et al. · Journal of Investigative Dermatology · 12

Development of a Multiplexed Urine Assay for Prostate Cancer Diagnosis

2008 · Tatiana Vener, Carlo Derecho, et al. · The Journal of Urology · 2

Correlation of RASGRP1:APTX expression assay with response to tipifarnib plus etoposide in elderly patients with newly diagnosed AML.

2011 · T. I. Vener, C. Derecho, et al. · Journal of Clinical Oncology · 1

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

2009 · Mitch Raponi, Tatiana Vener, et al. · Blood

A non-invasive urine-based research test for the detection of prostate cancer using DNA methylation

2007 · Tatiana Vener, Carlo Derecho, et al. · Cancer Research

Development of urine-based DNA methylation assay for prostate cancer screening

2007 · Tatiana Vener, Carlo Derecho, et al. · ORBi (University of Liège)

Works count: 9

Citation count: 117

H-index: 4

I10-index: 4